Related Experiment Video
Updated: Nov 1, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
The treatment landscape of metastatic prostate cancer
Yasutaka Yamada1, Himisha Beltran1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
The treatment landscape of metastatic prostate cancer has evolved significantly over the past two decades. Several landmark phase 3 trials led to new drug approvals and rapid changes in therapy options for patients, including drugs with distinct mechanisms of action (e.g., hormonal, chemotherapy, radionuclide, immunotherapy, and targeted therapies). Therapies initially developed in later stages of the disease (metastatic castration resistant prostate cancer) have started to move earlier in the prostate cancer continuum, with new standards of care for metastatic hormone naive prostate cancer and non-metastatic castration resistant prostate cancer. Overall, patients are living longer with a better quality of life. However, despite these significant advances, prostate cancer remains a leading cause of cancer death globally. Disease heterogeneity and the emergence of therapy resistance remain significant barriers, and the identification and application of molecular biomarkers to guide the choice and sequencing of systemic agents are still in early stages. Here we discuss the current treatment landscape of metastatic prostate cancer, clinical challenges, and the emerging role of molecular biomarkers for targeting biologic subsets of advanced disease and co-targeting heterogenous resistance patterns.
Insights
Metastatic prostate cancer treatment has advanced, improving patient outcomes. However, challenges like resistance and heterogeneity necessitate molecular biomarkers for personalized therapy selection.
Area of Science:
- Oncology
- Medical Science
- Pharmacology
Background:
- The treatment landscape for metastatic prostate cancer has undergone significant evolution over the last 20 years.
- Numerous phase 3 trials have resulted in new drug approvals and shifted therapeutic strategies across the prostate cancer continuum.
Purpose of the Study:
- To review the current treatment strategies for metastatic prostate cancer.
- To discuss existing clinical challenges and the emerging role of molecular biomarkers in advanced prostate cancer management.
Main Methods:
- Review of landmark phase 3 clinical trials and recent drug approvals in metastatic prostate cancer.
- Analysis of treatment shifts from later to earlier stages of the disease, including metastatic castration-resistant prostate cancer, metastatic hormone-naive prostate cancer, and non-metastatic castration-resistant prostate cancer.
Main Results:
- Significant advancements in therapies, including hormonal, chemotherapy, radionuclide, immunotherapy, and targeted agents, have improved patient survival and quality of life.
- Despite progress, prostate cancer remains a major global cause of cancer mortality, with disease heterogeneity and therapy resistance posing significant hurdles.
Conclusions:
- Molecular biomarkers are crucial for guiding the selection and sequencing of systemic agents in advanced prostate cancer.
- Targeting specific biologic subsets and addressing heterogeneous resistance patterns through biomarker-driven approaches are key future directions.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers